Revenue miss and rising R&D spend are near-term negatives, but the Phase 3 SUPRAME trial progress and strong cash runway through 2028 support the pipeline story. Traders should focus on SUPRAME PFS topline in H1 2027 as the key catalyst; near-term volatility likely on the mixed earnings print.
Drugs in focus
IMTX drug pipeline →IMA203
▲ Bullish Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- If Phase 3 succeeds, BLA submission is planned for 2027 with a potential commercial launch in 2027-2028.
- Next catalyst
- None dated
What to watchThe binary catalyst is the SUPRAME Phase 3 final PFS readout in H1 2027. Positive data would validate anzu-cel for BLA submission in 2027 and could drive significant upside toward analyst targets (~$17). A negative or underwhelming result would likely hit the stock hard given its current single-asset weighting. Interim operational updates on enrollment could come at the Q3 earnings call on Nov 16, 2026.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 18 $9.09entry
- T+1 · 3mo ago +1.76%α +1.55% · $9.25
- T+5 · 3mo ago +1.65%α +1.85% · $9.24
- T+20 · 2mo ago −2.97%α −1.98% · $8.82
- T+60 · 6d ago −29.37%α −27.33% · $6.42
Price Chart
How similar events traded
Executive Summary
Immatics reported Q2 2026 earnings with a narrower-than-expected net loss per share of -$0.46 (€-0.46), beating consensus EPS of -$0.48 by 9.5%, and revenue of $10.4M, below the $12.6M estimate. Key strategic updates include the SUPRAME Phase 3 trial remaining on track to complete enrollment by year-end, with topline PFS data expected H1 2027 and BLA submission in 2027, while aggregate events are occurring slower than modeled, prompting a shift to a single final analysis with enhanced OS power.
Key Financial Metrics
Key Facts
- Q2 2026 EPS of -$0.46 beat consensus of -$0.48 by 9.5%.
- Q2 2026 revenue of $10.4M (€9.1M) missed consensus estimate of $12.6M.
- Net loss narrowed to $71.2M (€62.5M) from $80.1M (€70.3M) in Q2 2025.
- Cash and equivalents stood at $448.2M (€393.4M) as of June 30, 2026, with cash reach into 2028.
- SUPRAME Phase 3 trial enrollment on track; topline PFS data expected H1 2027, BLA submission in 2027.
- Updated Phase 1b anzu-cel data showed 56% cORR, 14.6 months mDOR, 6.1 months mPFS, 16.2 months mOS in metastatic melanoma.
- IMA203CD8 showed 63% ORR and 50% cORR in gynecologic cancers at ASCO 2026.
- First patient dosed in Moderna collaboration (mRNA-4200) triggering a milestone payment.
- R&D expenses rose to $71.1M (€62.4M) from $51.4M (€45.1M) YoY due to SUPRAME trial advancement.
Financial Impact
EPS beat of ~9.5% partially offset by revenue miss of ~17.5% vs consensus; net loss improved YoY by ~11%.
Risk Factors
- Revenue miss and elevated R&D spending could pressure near-term sentiment.
- Phase 3 SUPRAME trial success is binary; slower event accrual adds execution risk.
- Pre-revenue biotech with no approved products; reliance on future trial readouts and regulatory approvals.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3346680 |
Track record
23 reports on IMTX
8 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +22.12% at T+20 after the May 12, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $6.24 Now $6.17 −1.12% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $6.55 Now $6.17 −5.73% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 5/10 No price data
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $6.42 Now $6.17 −3.89% settles Nov 17
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
- Oct 24, 202624d ago Press Release Bullish 6/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
- Oct 23, 202624d ago 6-K Bullish 7/10 Entry $7.31 to $7.20 Now $6.17 −15.60% ▼ −1.50% −0.95% vs SPY
- Aug 27, 202611w ago Insider Buy Bullish 6/10 Entry $9.45 to $9.56 Now $6.17 −34.71% ▲ +1.16% +1.05% vs SPY
- Aug 26, 202611w ago 6-K Bearish 6/10 Entry $9.36 to $9.46 Now $6.17 +34.08% ▼ −1.07% −0.80% vs SPY
- Aug 18, 202612w ago 6-K Neutral 6/10 Entry $9.09 to $9.24 Now $6.17 −32.12% ▲ +1.65% +1.85% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers